|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Operating activities | |||
| Net loss | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Bad debt expense | |||
| Depreciation and amortization | |||
| Finance cost on ELOC | |||
| Share-based compensation | |||
| Straight-line rent expense | |||
| Change in fair value of derivative liabilities | |||
| Receivables | |||
| Prepaid expenses and deposits | |||
| Non-cash interest expense | |||
| R&D costs for intangible assets | |||
| Gain on termination of intangible asset | |||
| Loss on sale of Skincare | |||
| Loss on disposal of PP&E | |||
| Gain on extinguishment of related-party debt | |||
| Realized loss on sale of investments | |||
| Unrealized loss on investments | |||
| Impairment on prepaid expense | |||
| Deferred tax expense | |||
| Changes in operating assets and liabilities: | |||
| Receivables | |||
| Prepaid expenses and deposits | |||
| Inventory | |||
| Accounts payable and accrued liabilities | |||
| Customer deposits | |||
| Due to related parties | |||
| Cash flows used in operating activities | |||
| Investing activities | |||
| Purchase of equipment | |||
| Purchase of intangible assets | |||
| Purchase of investments | |||
| Proceeds from sale of investments | |||
| Issuance of promissory note | |||
| Net cash paid in business combinations | |||
| Cash flows used in investing activities1 | |||
| Financing activities | |||
| Exercise of Series A warrants, net | |||
| Proceeds from the registered direct offering, net | |||
| Proceeds from issuance of Notes, net | |||
| Repayment of Notes | |||
| Exercise of stock options | |||
| Private Placement | |||
| Repurchase of shares and warrants | |||
| Issuance of common stock under ATM agreement, net | |||
| Exercise of replacement warrants, net | |||
| Proceeds from the initial Pre-Paid Purchase of ELOC, net | |||
| Cash flows provided by financing activities | |||
| Effect of exchange rate changes on cash | |||
| Increase in cash | |||
| Cash, beginning of year | |||
| Cash, ending of year | |||
| Supplemental cash flow information: | |||
| Cash paid for interest | |||
| Non-cash Investing and Financing transactions: | |||
| Conversion of preferred stock to common stock | |||
| Derivative liability broker warrants included in share issuance cost for IPO | |||
| Common stock issued and issuable on acquisition of intangible asset | |||
| Shares received as proceeds for the sale of Skincare | |||
| Series B preferred shares issues to settle accrued bonus liability | |||
| Consideration payable settled through termination of the agreement | |||
| Commitment shares on the ELOC | |||
| Common stock issued to settle a portion of the ELOC | |||
| Settled of outstanding promissory note in business combination |
Loading...
